St. Jude Medical Announces Start Of European Post-Approval Trial For Nanostim Leadless Pacemaker

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the first enrollments in the company’s LEADLESS Pacemaker Observational Study evaluating the Nanostim™ leadless pacing technology. The Nanostim pacemaker received CE Mark in 2013, and post-approval implants have occurred in the UK, Germany, Italy, Czech Republic, France, Spain, and the Netherlands.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC